Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic ...

Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock ...

Novo Nordisk and Valo Health have expanded their 16-month-old collaboration into an up-to-$4.6 billion-plus artificial ...

Novo Nordisk also boasted a 55.6% share of the GLP-1 drug space, compared to 54.4% as of August 2023. The company's most famous brands, Wegovy and Ozempic, are both GLP-1s.

Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of drugs that are allowed to be compounded. In a Citizen Petition posted on ...

Novo Nordisk (NYSE: NVO) and AstraZeneca (NASDAQ: AZN) are among the largest companies in the pharmaceutical industry. Both have generally produced strong financial results in 2024, but one wouldn ...

Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and ...

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for legal issues in China. One of these stocks has a stronger investment ...

The move intensifies an ongoing legal battle, as Novo Nordisk joins its major competitor Eli Lilly in opposing a recent initiative by the Outsourcing Facilities Association to include liraglutide in ...

Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to ...

To hear Novo tell it, the outsourcing group OFA shouldn’t be allowed to place liraglutide on its compounding list given that FDA-approved generics to Victoza are available. Further, the OFA has ...